<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170301032837N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-12-03</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of infusion of propofol before it's induction dose on injection pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of the effect of propofol infusion before injection of induction dose on injection induced pain and changes in serum complement in patients candidate for general anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-02-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/25486</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this research, simple randomization method is used using sealed envelope. The patient chooses one of the three envelopes, in which the letters A, B, C are written, and is placed in one of the three groups, Blinding description: During the study, the patient is simply blind because of the lack of knowledge about how the anesthetic induction was performed.The laboratory, which is responsible for assessing the serum level of complementary C3 factor, is blind. The researcher is involved in the induction of anesthesia and intervention, and is not blind to the type of intervention and non-intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pain caused by propofol injection.</hc_freetext>
      <i_freetext>Intervention 1: Control group: After IV catheterizationin the patient's hand, 5 cc blood samples are taken to measure the serum level of complement factor C3. One minute later fentanyl 3 micg/kg and midazolam 0.15 mg/kg is injected. One minute later, general anesthesia is induced with propofol 2 mg/kg and atracurium 0.5 mg/kg.One minute later, 5 cc blood sample are taken from the same hand and above the injection site to measure the serum level of factor C3.During injection of Bolus Propofol, pain intensity is assessed by VAS. Intervention 2: Intervention group 1: After intravenous catheterization, 5 cc blood samples are taken to measure the serum level of complement factor C3.Then propofol infusion 50μg/kg/min  ( Manufactured by: Fresenius Kabi Ausria GmbH A-8055 Graz , Austria ) is administered for one minute. Then fentanyl 3 μg/kg and midazolam 0.15 mg/kg are injected.One minute later, general anesthesia is induced with propofol 2 mg/kg and atracurium 0.5 mg/kg.One minute later, 5 cc blood sample are taken from the same hand and above the injection site to measure the serum level of factor C3.During injection of Bolus Propofol, pain intensity is assessed by VAS. Intervention 3: Intervention group 2: After intravenous catheterization, 5 cc blood samples are taken to measure the serum level of complement factor C3.Then propofol infusion 100μg/kg/min ( Manufactured by: Fresenius Kabi Ausria GmbH A-8055 Graz , Austria ) is administered for one minute. Then fentanyl 3 μg/kg and midazolam 0.15 mg/kg are injected.One minute later, general anesthesia is induced with propofol 2 mg/kg and atracurium 0.5 mg/kg.One minute later, 5 cc blood sample are taken from the same hand and above the injection site to measure the serum level of factor C3.During injection of Bolus Propofol, pain intensity is assessed by VAS.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All information used for this research can be shared after unidentifying the identity of patients. Also, statistical information, information analysis, study method, findings and conclusions can be shared.

When:
Starting access after accepting by a valid scientific journal and publishing it

To whom:
For academic researchers and in the field of science

Conditions:
All researchers can use all published material and if all or part of this research is published by other people, the name and source of this research and its researchers should be mentioned.

Where to obtain:
Dr. Behrooz Zaman
Email: zaman.b@iums.ac.ir

How to obtain:
The applicant can request the type of files by email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behrooz Zaman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran university of medical sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8871 7272</telephone>
        <email>zaman.b@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behrooz Zaman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran university of medical sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8871 7272</telephone>
        <email>zaman.b@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients are candidates for general anesthesia ASA I &amp; II</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>uncontrolled chronic and acute diseases
age &gt;60
age&lt;18
history of hypersensitivity to drugs and foods
History of using NSAIDS and corticostroides
opioid addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T41.1X5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Adverse effect of intravenous anesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: After IV catheterizationin the patient's hand, 5 cc blood samples are taken to measure the serum level of complement factor C3. One minute later fentanyl 3 micg/kg and midazolam 0.15 mg/kg is injected. One minute later, general anesthesia is induced with propofol 2 mg/kg and atracurium 0.5 mg/kg.One minute later, 5 cc blood sample are taken from the same hand and above the injection site to measure the serum level of factor C3.During injection of Bolus Propofol, pain intensity is assessed by VAS.</i_keyword>
      <i_keyword>Intervention group 1: After intravenous catheterization, 5 cc blood samples are taken to measure the serum level of complement factor C3.Then propofol infusion 50μg/kg/min  ( Manufactured by: Fresenius Kabi Ausria GmbH A-8055 Graz , Austria ) is administered for one minute. Then fentanyl 3 μg/kg and midazolam 0.15 mg/kg are injected.One minute later, general anesthesia is induced with propofol 2 mg/kg and atracurium 0.5 mg/kg.One minute later, 5 cc blood sample are taken from the same hand and above the injection site to measure the serum level of factor C3.During injection of Bolus Propofol, pain intensity is assessed by VAS.</i_keyword>
      <i_keyword>Intervention group 2: After intravenous catheterization, 5 cc blood samples are taken to measure the serum level of complement factor C3.Then propofol infusion 100μg/kg/min ( Manufactured by: Fresenius Kabi Ausria GmbH A-8055 Graz , Austria ) is administered for one minute. Then fentanyl 3 μg/kg and midazolam 0.15 mg/kg are injected.One minute later, general anesthesia is induced with propofol 2 mg/kg and atracurium 0.5 mg/kg.One minute later, 5 cc blood sample are taken from the same hand and above the injection site to measure the serum level of factor C3.During injection of Bolus Propofol, pain intensity is assessed by VAS.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: At the time of the intervention. Method of measurement: visual analogue scale of pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Changes in serum level of complement factor C3. Timepoint: Immediately before the intervention and two minutes after the intervention. Method of measurement: Blood sampling and laboratory measurements.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-02-12</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Hemmat highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
